Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry

Publisher： John Wiley & Sons Inc

E-ISSN： 2326-5205|66|9|2580-2589

ISSN： 2326-5191

Source： ARTHRITIS & RHEUMATOLOGY, Vol.66, Iss.9, 2014-09, pp. : 2580-2589

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 11, 2015-11 ,pp. : 1529-1535

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 12, 2014-12 ,pp. : 3463-3475

John Wiley & Sons Inc

Access to resources Recommend Favorite

From childhood to adult life with juvenile idiopathic arthritis (JIA): A pilot study

By Östlie Ingrid   Dale Öystein   Möller Anders  

Disability and Rehabilitation, Vol. 29, Iss. 6, 2007-01 ,pp. : 445-452

Informa Healthcare

Access to resources Recommend Favorite

Long-term experience with biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis

By Klein Ariane   Horneff Gerd  

Clinical Investigation, Vol. 3, Iss. 5, 2013-05 ,pp. : 493-504

Future Science

Access to resources Recommend Favorite

Randomized, Double‐Blind, Placebo‐Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 9, 2014-09 ,pp. : 2570-2579

John Wiley & Sons Inc

Access to resources Recommend Favorite